西洛他唑在冠心病介入治疗中的临床应用  

Clinical Application of Cilostazol in Coronary Interventional Therapy

作　　者：布伦[1] 唐发宽[1] 齐帜[1] 王德水[1] 陈小刚[1] 

机构地区：[1]解放军第309医院 心内科,北京100091

出　　处：《中国医刊》2011年第12期37-39,共3页Chinese Journal of Medicine

基　　金：院立课题资助项目(编号309-09-13)

摘　　要：目的评价经皮冠状动脉介入治疗(PCI)后,氯吡格雷抵抗患者增加服用两洛他唑的有效性及安全性。方法依据血栓弹力图(TEG)的测定结果,将入选的112例氯吡格雷抵抗患者分为双联药物组57例与三联药物组55例,随访观察两组患者PCI术后6个月时临床缺血及出出血事件的发生率。结果三联药物组与双联药物组患者相比较,主要不良心血管事件的发生率明显降低,而出血事件发生率在两组患者间比较,差异无显著性。结论增加服用西洛他唑,可以减少冠心病患者PCI术后缺血事件的发生,且不增加患者的出血风险。Objective To evaluate the efficiency and safety of the patients with clopidogrel resistance prescribed with cilostazol undergoing percutaneous coronary intervention （PCI）. Methods 112 patients with clopidogrel resistance were divided into dual antiplatelet therapy group （57 cases） and triple antiplatelet therapy group （55cases） according to the result of thromboelastography（ TEG）, the ischemic and bleeding events of two group patients were analysed during in-hospital stay and clinical follow up of 6 months. Results Compared with the dual antiplatelet therapy group, the incidence of major adverse cardiac events （MACE） was lower in the triple antiplatelet therapy group. And there were no significant differences in the incidence of bleeding events between two groups. Conclusions Our data indicate that the incidence of ischemic events of patients with coronary heart disease undergoing PCI may be de- creased by increasing the drug of cilostazol, and the risk of bleeding may be not increased.

关 键 词：氯吡格雷抵抗 经皮冠状动脉介入治疗 血小板聚集 西洛他唑 

分 类 号：R541[医药卫生—心血管疾病]